Clinical Trial Detail

NCT ID NCT02468661
Title A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Capmatinib

Capmatinib + Erlotinib

Erlotinib

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: senior adult

No variant requirements are available.